loading...

Rob Rodrigues

Rob Rodrigues VCARD
Download PDF Profesional Biography

Rob Rodrigues

Partner

roberto.rodrigues@lickslegal.com

+55 21 3550 3723

+55 21 99813 4328

Rob Rodrigues manages high-stakes business and intellectual property disputes in Brazil. He assists his clients in complex matters ranging from managing patent prosecution portfolios to enforcement and monetization. Rob is an experienced attorney and acted as lead counsel in several preliminary injunction proceedings and patent trials. In addition, Rob aids clients with transactions involving businesses in their portfolio. Mr. Rodrigues’ litigation-oriented mindset adds value when managing cross border risks.

Rob is regularly recognized by leading publications, including The Legal 500 and IP Stars, with client sources describing him as “greatly skilled at advising on the most complex and high-profile M&A transactions,” and noting that he “combines strong technical skills and a flair for complexity with commercial awareness, pragmatism and sound judgment.” Rob earned an LLM from Stanford Law School, where he was Lead Editor of the Stanford Technology Law Review. He joined Licks Attorneys again in 2019 after working at Quinn Emanuel Urquhart & Sullivan, LLP in New York City. He has also published articles in technology law journals around the world and is currently an editor of the Kluwer Patent Blog.

Languages
  • Portuguese
  • English
  • Spanish
Practice Areas
  • Copyright & Software
  • Data Protection
  • Food & Drug Law
  • Internet & Software
  • Licensing
  • Patents
  • Regulatory
  • Trade Secrets & Regulatory
Representative Cases
  • Trial associate for biopharmaceutical company in patent enforcement against biosimilar companies
  • Associate for startup company in defense of abusive behavior action
  • Counsel for pharmaceutical company in an antitrust case involving sham litigation claims.
Professional Highlights
  • The Legal 500 - ‘Recommended’ Life Sciences Practice (2023, 2022);
  • IP Stars- ‘Notable Practitioner (2022, 2021);
  • Leaders League – Life Sciences (2022);
  • IP Stars- ‘IP Star’ Rising Star (2019);
  • Quinn Emanuel Urquhart & Sullivan, LLP, foreign associate (2017-2018);
  • Stanford Technology Law Review: lead editor;
  • Hoover IP2 Summer Teaching Institute – Residential Scholarship (2017).
Representative Experience
  • Trial associate for biopharmaceutical company in patent enforcement against biosimilarcompanies;
  • Associate for startup company in defense of abusive behavior action;
  • Counsel for pharmaceutical company in an antitrust case involving sham litigation claims.
Affiliations

• Brazilian Bar Association – Rio de Janeiro Section (OAB/RJ).

Education
  • Stanford Law School (LLM in Law, Science and Technology 2017);
  • Bachelor of Laws (LL.B), Universidade Federal do Rio de Janeiro (2013)
Publications
  • Co-author: New Regulation of Cannabis-Based Drugs Coming Soon (Update Magazine, a publication of the Food and Drug Law Institute (FDLI), November/December 2019).
  • Miller, Shawn P. and Aravind, Ashwin and Bengfort, Bethany and De La Cerda, Clarisse and Dragoni, Matteo and Gibson, Kevin and Itai, Amit and Johnson, Charles and Kannappan, Deepa and Kehoe, Emily and Kim, Hyosang and Mladinich, Katherine and Pinho, Roberto and Polansky, John and Weissenberg, Brian, Who’s Suing Us? Decoding Patent Plaintiffs since 2000 with the Stanford NPE Litigation Dataset (July 18, 2018). Stanford Technology Law Review, Vol. 21, No. 234, 2018.
  • Enforcing pending patent applications in Brazil: a different approach to dealing with the backlog (12, 2017 publication descriptionOxford Journal of Intellectual Property Law & Practice)
  • Co-author: “Gauging the Future of Biosimilars in Brazil: Looking Ahead after the Approval of the Monoclonal Remsima” (GEN Exclusives, 2015) (http://www.genengnews.com/public/ AnalysisAndInsight/item.aspx?id=77900537&a=false).
  • Co-author: “Patent Knowledge Share: Brazil” (The Patent Lawyer Magazine, September/October 2015).
  • Co-author: “The Business of Immuno-Oncology” (http://www.genengnews.com/gen-exclusives/ the-business-of-immuno-oncology/77900600).
  • Author: “Brazil: Pharmacovigilance Risk in Evolving Biosimilar Regulation” (Update Magazine, a publication of the Food and Drug Law Institute (FDLI), March/April 2015).

 

Articles